Alnylam stock sinks after last-minute changes in key drug trial

Alnylam Pharmaceuticals Inc. saw its stock price sink to its lowest point in the last year after the Cambridge company announced changes to a Phase 3 clinical trial that's already underway.

Source: bizjournals.com Health Care:Biotechnology headlines - February 16, 2024 Category: Biotechnology Authors: Hannah Green Source Type: news